Improvement of peptide-based tumor immunotherapy using pH-sensitive fusogenic polymer-modified liposomes

Yuta Yoshizaki, Eiji Yuba, Toshihiro Komatsu, Keiko Udaka, Atsushi Harada, Kenji Kono

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


To establish peptide vaccine-based cancer immunotherapy, we investigated the improvement of antigenic peptides by encapsulation with pH-sensitive fusogenic polymer-modified liposomes for induction of antigen-specific immunity. The liposomes were prepared by modification of egg yolk phosphatidylcholine and L-dioleoyl phosphatidylethanolamine with 3-methyl-glutarylated hyperbranched poly(glycidol) (MGlu-HPG) and were loaded with antigenic peptides derived from ovalbumin (OVA) OVA-I (SIINFEKL), and OVA-II (PSISQAVHAAHAEINEAPβA), which bind, respectively, to major histocompatibility complex (MHC) class I and class II molecules on dendritic cell (DCs). The peptide-loaded liposomes were taken up efficiently by DCs. The peptides were delivered into their cytosol. Administration of OVA-I-loaded MGlu-HPG-modified liposomes to mice bearing OVA-expressing E.G7-OVA tumors induced the activation of OVA-specific CTLs much more efficiently than the administration of free OVA-I peptide did. Mice strongly rejected E.G7-OVA cells after immunization with OVA-I peptide-loaded MGlu-HPG liposomes, although mice treated with free OVA-I peptide only slightly rejected the cells. Furthermore, efficient suppression of tumor volume was observed when tumor-bearing mice were immunized with OVA-I-peptide-loaded liposomes. Immunization with OVA-II-loaded MGlu-HPG-modified liposomes exhibited much lower tumor-suppressive effects. Results indicate that MGlu-HPG liposomes might be useful for improvement of CTL-inducing peptides for efficient cancer immunotherapy.

Original languageEnglish
Article number1284
Issue number10
Publication statusPublished - 2016 Oct 1


  • Dendritic cell
  • Immunotherapy
  • Peptide vaccine
  • pH-sensitive liposome
  • pH-sensitive polymer


Dive into the research topics of 'Improvement of peptide-based tumor immunotherapy using pH-sensitive fusogenic polymer-modified liposomes'. Together they form a unique fingerprint.

Cite this